Glycoconjugation: An Approach to Cancer Therapeutics

Overview

Journal World J Clin Oncol

Publisher Baishideng Publishing Group

Specialty Oncology

Date 2020 Apr 8

PMID 32257842

Citations 10

Authors

Maria I Molejon

Gisela Weiz

Javier D Breccia

Maria Ines Vaccaro

Affiliations

Soon will be listed here.

Abstract

Cancer constitutes the second leading cause of death globally and is considered to have been responsible for an estimated 9.6 million fatalities in 2018. Although treatments against gastrointestinal tumors have recently advanced, those interventions can only be applied to a minority of patients at the time of diagnosis. Therefore, new therapeutic options are necessary for advanced stages of the disease. Glycosylation of antitumor agents, has been found to improve pharmacokinetic parameters, reduce side effects, and expand drug half-life in comparison with the parent compounds. In addition, glycosylation of therapeutic agents has been proven to be an effective strategy for their targeting tumor tissue, thereby reducing the doses of the glycodrugs administered to patients. This review focusses on the effect of the targeting properties of glycosylated antitumor agents on gastrointestinal tumors.

Citing Articles

Envisioning Glucose Transporters (GLUTs and SGLTs) as Novel Intervention against Cancer: Drug Discovery Perspective and Targeting Approach.

Shafi S, Ahmed Khan M, Ahmad J, Rabbani S, Singh S, Najmi A Curr Drug Targets. 2024; 26(2):109-131.

PMID: 39377414 DOI: 10.2174/0113894501335877240926101134.

The Anticancer Activity of Monosaccharides: Perspectives and Outlooks.

McCallum N, Najlah M Cancers (Basel). 2024; 16(16).

PMID: 39199548 PMC: 11353049. DOI: 10.3390/cancers16162775.

Rutinosides-derived from Sarocladium strictum 6-O-α-rhamnosyl-β-glucosidase show enhanced anti-tumoral activity in pancreatic cancer cells.

Weiz G, Gonzalez A, Mansilla I, Fernandez-Zapico M, Molejon M, Breccia J Microb Cell Fact. 2024; 23(1):133.

PMID: 38720294 PMC: 11077868. DOI: 10.1186/s12934-024-02395-0.

Targeting Pivotal Hallmarks of Cancer for Enhanced Therapeutic Strategies in Triple-Negative Breast Cancer Treatment-In Vitro, In Vivo and Clinical Trials Literature Review.

Szulc A, Wozniak M Cancers (Basel). 2024; 16(8).

PMID: 38672570 PMC: 11047913. DOI: 10.3390/cancers16081483.

Negative Charge-Carrying Glycans Attached to Exosomes as Novel Liquid Biopsy Marker.

Kosutova N, Lorencova L, Hires M, Jane E, Orovcik L, Kollar J Sensors (Basel). 2024; 24(4).

PMID: 38400284 PMC: 10892626. DOI: 10.3390/s24041128.

References

Garnier P, Wang X, Robinson M, van Kasteren S, Perkins A, Frier M . Lectin-directed enzyme activated prodrug therapy (LEAPT): Synthesis and evaluation of rhamnose-capped prodrugs. J Drug Target. 2010; 18(10):794-802. DOI: 10.3109/1061186X.2010.529909. View

Xing J, Song G, Deng J, Jiang L, Xiong P, Yang B . Antitumor Effects and Mechanism of Novel Emodin Rhamnoside Derivatives against Human Cancer Cells In Vitro. PLoS One. 2015; 10(12):e0144781. PMC: 4684281. DOI: 10.1371/journal.pone.0144781. View

Wu J, Liu Q, Lee R . A folate receptor-targeted liposomal formulation for paclitaxel. Int J Pharm. 2006; 316(1-2):148-53. DOI: 10.1016/j.ijpharm.2006.02.027. View

Warburg O . On the origin of cancer cells. Science. 1956; 123(3191):309-14. DOI: 10.1126/science.123.3191.309. View

Pashov A, Monzavi-Karbassi B, Raghava G, Kieber-Emmons T . Bridging innate and adaptive antitumor immunity targeting glycans. J Biomed Biotechnol. 2010; 2010:354068. PMC: 2896669. DOI: 10.1155/2010/354068. View

Robinson M, Charlton S, Garnier P, Wang X, Davis S, Perkins A . LEAPT: lectin-directed enzyme-activated prodrug therapy. Proc Natl Acad Sci U S A. 2004; 101(40):14527-32. PMC: 521935. DOI: 10.1073/pnas.0303574101. View

Annibaldi A, Widmann C . Glucose metabolism in cancer cells. Curr Opin Clin Nutr Metab Care. 2010; 13(4):466-70. DOI: 10.1097/MCO.0b013e32833a5577. View

Rao D, Parakrama R, Augustine T, Liu Q, Goel S, Maitra R . Immunotherapeutic advances in gastrointestinal malignancies. NPJ Precis Oncol. 2019; 3:4. PMC: 6363766. DOI: 10.1038/s41698-018-0076-8. View

Thorens B, Mueckler M . Glucose transporters in the 21st Century. Am J Physiol Endocrinol Metab. 2009; 298(2):E141-5. PMC: 2822486. DOI: 10.1152/ajpendo.00712.2009. View

10.

Supko J, HICKMAN R, Grever M, Malspeis L . Preclinical pharmacologic evaluation of geldanamycin as an antitumor agent. Cancer Chemother Pharmacol. 1995; 36(4):305-15. DOI: 10.1007/BF00689048. View

11.

Kwak H, Park M, Park C, Moon S, Yoo D, Lee H . Emodin inhibits vascular endothelial growth factor-A-induced angiogenesis by blocking receptor-2 (KDR/Flk-1) phosphorylation. Int J Cancer. 2006; 118(11):2711-20. DOI: 10.1002/ijc.21641. View

12.

Carrascal M, Severino P, Cabral M, Silva M, Ferreira J, Calais F . Sialyl Tn-expressing bladder cancer cells induce a tolerogenic phenotype in innate and adaptive immune cells. Mol Oncol. 2014; 8(3):753-65. PMC: 5528624. DOI: 10.1016/j.molonc.2014.02.008. View

13.

Xu L, Liu X, Li Y, Yin Z, Jin L, Lu L . Enzymatic rhamnosylation of anticancer drugs by an α-L-rhamnosidase from Alternaria sp. L1 for cancer-targeting and enzyme-activated prodrug therapy. Appl Microbiol Biotechnol. 2019; 103(19):7997-8008. DOI: 10.1007/s00253-019-10011-0. View

14.

Medina R, Owen G . Glucose transporters: expression, regulation and cancer. Biol Res. 2002; 35(1):9-26. DOI: 10.4067/s0716-97602002000100004. View

15.

de Bono J, Ashworth A . Translating cancer research into targeted therapeutics. Nature. 2010; 467(7315):543-9. DOI: 10.1038/nature09339. View

16.

Gonzalez C, Alvarez S, Ropolo A, Rosenzvit C, Gonzalez Bagnes M, Vaccaro M . Autophagy, Warburg, and Warburg reverse effects in human cancer. Biomed Res Int. 2014; 2014:926729. PMC: 4145381. DOI: 10.1155/2014/926729. View

17.

Calvaresi E, Hergenrother P . Glucose conjugation for the specific targeting and treatment of cancer. Chem Sci. 2013; 4(6):2319-2333. PMC: 3784344. DOI: 10.1039/C3SC22205E. View

18.

Rooseboom M, Commandeur J, Vermeulen N . Enzyme-catalyzed activation of anticancer prodrugs. Pharmacol Rev. 2004; 56(1):53-102. DOI: 10.1124/pr.56.1.3. View

19.

Fitzmaurice C, Allen C, Barber R, Barregard L, Bhutta Z, Brenner H . Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-years for 32 Cancer Groups, 1990 to 2015: A Systematic Analysis for the Global Burden of Disease Study. JAMA Oncol. 2016; 3(4):524-548. PMC: 6103527. DOI: 10.1001/jamaoncol.2016.5688. View

20.

Sathornsumetee S, Rich J . Molecularly targeted therapy in neuro-oncology. Handb Clin Neurol. 2012; 104:255-78. DOI: 10.1016/B978-0-444-52138-5.00018-9. View